News

With the help of software, NoVa’s Jeeva wants to increase access to clinical trials

The Manassas, Virginia SaaS company is making it easier for remote patients to connect with clinical trial data.

Virginia founder Harsha Rajasimha sees clinical trials as a crucial piece of the healthcare puzzle. But not everyone gets to take advantage of them.

Before he launched a startup, Rajasimha was just an older brother who had watched his brother deal with diabetes for over a decade. But his India-based sibling was unable to find a clinical trial to take part in, as the majority take place in Europe and the US.

“Clinical trials, which are essentially at no cost to patients as their sponsor pays for the cost of the clinical trial, are, by definition, better than the standard of care,” Rajasimha told Technical.ly. “Instead of relying on the insulin injections once a day or twice a day, you can actually find something better than that option.”

To help, he created Jeeva Informatics Solutions, a Manassas, Virginia-based SaaS company for clinical trials that just received an investment from Virginia Innovation Partnership Corporation’s (VIPC) Virginia Venture Partners. Clinical researchers, public health organizations, contract research organizations and biotech and pharmaceutical companies can use Jeeva’s cloud platform to recruit patients. Meanwhile, the company’s software helps with remote patient screening, data collection, patient engagement, regulatory compliance and IT security without relying on additional hardware or technology. This helps with workflow, Rajasimha said, and increases access to clinical trials.

Making clinical trials more online-compatible, he thinks, can increase the number of patients and lead to fewer dropouts. The Jeeva configuration can also be used for multiple years as trials, which last about 18 months on average, can go as long as five or 10 years. The Jeeva platform can be licensed directly by a biopharma or clinical research institution, as well, and create a patient registry for use.

Rajasimha thinks that making this more accessible will mean more data is available to patients considering trials.

“Patients don’t have the motivation to take time off from work and go to a clinical trial site without any potential return on their time investment,” Rajasimha said. “So it becomes critical that we have access to a platform like Jeeva that can enable the creation and maintenance of these data collection studies over a long period of time, with or without treatment being part of the protocol.”

Jeeva’s 20-person team built the platform in its entirety by creating the initial product before converting it into a scaleable product on the cloud. The platform and database were built on Python and React.

The team has been hard at work creating the minimum viable product over the past three-and-a-half years. It now hopes to grow for global adoption with the new funds. Rajasimha added that Jeeva has also established partnerships with research organizations in the US, South America and India.

But he doesn’t plan on stopping there. In addition to the $300,000 the company received from VIPC, he is continuing to raise another $400,000 over the next two to three months. Overall, the funds will be used for growing and expanding the company as well as building additional technology — especially for more diverse user pools. Jeeva’s product is currently built primarily for English-speaking populations, so he hopes to expand its offerings to be more inclusive.

“That’s what we will be focusing on in the next phase of our company’s growth: making the platform more inclusive of diverse patient populations,” Rajasimha said.

Read more here.

Recent News

04/23/2025

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories

04/22/2025

Phlow Corp. Expands Analytical Capabilities and Embraces Artificial Intelligence-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America

Phlow Corp., a leading pharmaceutical contract development and manufacturing organization (CDMO) in America, announced a significant expansion in its analytical capabilities, use of artificial intelligence (AI), workforce, and domestic infrastructure. Marking a period of exceptional growth and momentum, Phlow has more than doubled in size and now employs over 90+ highly skilled scientists and professionals

04/22/2025

ATCC Announces New Executive Leadership Appointments

ATCC, the world’s premier biological materials management and standards organization, today announced several new leadership appointments. Rebecca Bradford, MBA, has been promoted to the role of senior vice president of Government Programs, ATCC Federal Solutions (AFS); Manoj Menon, PhD, has joined the company as chief operating officer; and Rupali Lach was appointed vice president of Commercial Operations.